Alcon's PATANASE(R) Nasal Spray Approved By FDA For Treatment Of Nasal Allergy Symptoms
Alcon, Inc. (NYSE: ACL) announced that the U.S. Food and Drug Administration (FDA) has approved PATANASE® (olopatadine hydrochloride) nasal spray for the relief of the symptoms of seasonal allergic rhinitis in patients 12 years of age and older. PATANASE® nasal spray, an extension to Alcon's market-leading ocular allergy product line, will be available in May of this year. (Source: Ear, Nose and Throat News From Medical News Today)div id=medwormpbiMedWorm Message:/i/b Please have a look at this new site driven by MedWorm: a href=http://www.thebreastcancerdaily.com/ target=_blankThe Breast Cancer Daily/a/p/div

Cancer's 'Field Effect' Enables Earlier Detection Of Pancreatic Cancer During Routine Endoscopy
By simply shining a tiny light within the small intestine, close to that organ's junction with the pancreas, physicians at Mayo Clinic's campus in Florida have been able to detect pancreatic cancer 100 percent of the time in a small study. The light, attached to a probe, measures changes in cells and blood vessels in the small intestine produced by a growing cancer in the adjoining pancreas. This minimally invasive technique, called Polarization Gating Spectroscopy, will now be tested in a much larger international clinical trial led by the Mayo Clinic researchers... (Source: Health News from Medical News Today)